Neuropathic pain is often refractory to intervention because of the complex etiology and an incomplete understanding of the mechanisms behind this type of pain. Glial cells, specifically microglia and astrocytes, are powerful modulators of pain and new targets of drug development for neuropathic pain. Glial activation could be the driving force behind chronic pain, maintaining the noxious signal transmission even after the original injury has healed. Glia express chemokine, purinergic, toll-like, glutaminergic and other receptors that enable them to respond to neural signals, and they can modulate neuronal synaptic function and neuronal excitability. Nerve injury upregulates multiple receptors in spinal microglia and astrocytes. Microglia influence neuronal communication by producing inflammatory products at the synapse, as do astrocytes because they completely encapsulate synapses and are in close contact with neuronal somas through gap junctions. Glia are the main source of inflammatory mediators in the central nervous system. New therapeutic strategies for neuropathic pain are emerging such as targeting the glial cells, novel pharmacologic approaches and gene therapy. Drugs targeting microglia and astrocytes, cytokine production, and neural structures including dorsal root ganglion are now under study, as is gene therapy. Isoform-specific inhibition will minimize the side effects produced by blocking all glia with a general inhibitor. Enhancing the anti-inflammatory cytokines could prove more beneficial than administering proinflammatory cytokine antagonists that block glial activation systemically. Research on therapeutic gene transfer to the central nervous system is underway, although obstacles prevent immediate clinical application. 
drug development. Activated glia release multiple signaling molecules that enhance central processing of noxious signaling. Glial signaling has pro-inflammatory effects on both nervous and immune system structures, sometimes with pathological effects including neuronal hyperexcitability, neurotoxicity, neuronal plasticity and chronic inflammation. However, glial activation in the CNS may also have beneficial effects that contribute to a local immune environment, such as the release and maintenance of anti-inflammatory factors, restoration of normal noxious signal transmission and protection against neurotoxicity. Even with advanced treatments, neuropathic pain is often refractory to intervention because of the often complex etiology and an incomplete understanding of the mechanisms behind this type of pain. Despite progress in analgesic drug discovery, the need for therapeutic agents capable of blocking enhanced noxious signal transmission without impairing normal abilities remains largely unmet. 2) Therefore, new therapeutic strategies are needed such as targeting the glial cells, novel pharmacologic approaches and gene therapy. According to recent findings that highlight the active participation of glial cells in the onset and/or maintenance of chronic pain, [3] [4] [5] glia could be potential targets for neuropathic pain control. Moreover, for patients who fail interventional or pharmacological therapies, gene therapy may promise improved pain control, although currently it is primarily experimental. In this review, our focus is on the dorsal horn of the spinal cord. We describe briefly several potential mechanisms of neuropathic pain involving glia at the level of the CNS. We also describe current pharmacological trials targeting the glia, and discuss the possibilities of gene therapy.
PART I: BASIC SCIENCE
Nociceptive transmission is normal physiology mediated by multisynaptic pathways, and it initiates processing at multiple sites in the CNS. When injury or inflammation is prolonged, ongoing excitation of primary nociceptive neurons can cause chronic pain. Altered activity in spinal cord and/or brain neurons is relevant in noxious transmission, as well as abnormal firing patterns in primary sensory nociceptors, leads to chronic neuropathic pain. 6) Sustained tissue injury or inflammation in the CNS can also sensitize neurons in the spinal cord, leading to chronic pain. 7, 8) Nerve damage evokes a cascade of immune responses, which may play a role in initiating neuropathic pain, maintaining neuropathic pain acutely and/or play a role in chronic neuropathic pain. 6) Nociceptors have a rich variety of immune receptors, and evidence exists for roles of the interleukins (IL-1β, IL-6 and IL-8), TNF-α, bradykinin, prostanoids, and other. Although epinephrine produces mechanical hyperalgesia and sensitizes DRG mediated by both the protein kinase A and C pathways, 9) and reduced potassium chloride co-transporter expression and increased GABA release contribute to hyperalgesia, 10) pro-inflammatory substances, in particular, pro-inflammatory cytokines (TNF-α, IL-1, IL-2, and IL-6), cyclooxygenase-2, and inducible nitric oxide synthase (iNOS) promote the activation of microglia and the production of inflammatory mediators that acting on nociceptive pathway, lead to central sensitization as well as peripheral and hence, to the development and maintenance of persistent pain states.
Central immune system
Peripheral nerve injuries such as complex regional pain Specifically, nerve injury upregulates several receptors, such as the chemokine receptor CX3CR1 and ATP receptor P2X4 and P2Y12 in spinal microglia. [14] [15] [16] [17] [18] The chemokine receptor CCR2 and Toll-like receptor-4 are also expressed in spinal microglia and contribute to neuropathic pain sensitization. 19, 20) Fractalkine is a unique chemokine that plays an important role in mediating neural-glial interaction. Also, fractalkine acts on CX3CR1 receptor to release IL-1β from spinal microglia. Nerve injury induces a marked cleavage of fractalkine in the DRG, which bind to its upregulated CX3CR1 receptor in spinal microglia, and then it leads to the activation of the p38 MAPK signaling cascade. 16 14) showed that the activation of microglia in neuropathy requires P2X4 receptors. However, Raouf et al. 26) raised the question of: 1) whether the upregulation of P2X4 receptors takes place downstream of signaling events specifically triggered in conditions of 
26)
In addition to p38 signaling pathway activation in spinal microglia, extracellular signal regulated kinase (ERK),
another MAPK family member, is also activated in spinal microglia at early stages of neuropathic pain development.
The activation of ERK is necessary for neuropathic pain sensitization. 30) In acute and inflammatory pain conditions, ERK is activated in dorsal horn neurons, and this con- (Fig. 2) .
Spinal cord injury induces an immediate increase in plasma endothelin (ET) levels and a sustained increase in tissue ET levels. ET-1 also induces hypertrophy of astrocytes. 46) ET receptor-B (ETB) is induced in spinal astrocytes after spinal cord injury (Fig. 2 ).
47)
In acute and inflammatory pain conditions, ERK is activated in dorsal horn neurons, which contributes to the induction and maintenance of dorsal horn neuron sensitization and pain hypersensitivity. 48, 49) Phosphorylated ERK (pERK), which is the active form, is found in microglia on day 2, in both microglia and astrocytes on day 10, and in astrocytes only on 21. 
51)
Basic fibroblast growth factor (bFGF) is a pleiotropic cytokine synthesized and secreted by astrocytes and DRG primary sensory neurons. It strongly induces astrocyte mitosis, growth, differentiation and gliosis. 52, 53) bFGF is induced in the CNS in many injury conditions. After spinal cord injury, bFGF upregulates in the spinal cord, which promotes functional recovery. [54] [55] [56] The release of bFGF from astrocytes probably acts in an autocrine manner to further augment astroglial activation (e.g. astrogliosis and proliferation) (Fig. 2) . Because bFGF is a primary 'activator' of astrocytes and JNK is an important signaling molecule in spinal astrocytes, it is reasonable to ask whether bFGF activates JNK in spinal astrocytes. Intrathecal infusion of bFGF induces a marked activation of JNK in the spinal cord. bFGF also induces marked acti- 
Targeting microglial activation
Several studies have shown that specific microglial inhibitors and/or modulators can block and/or reverse neuropathic states. [58] [59] [60] The most commonly used drugs are fluorocitrate and minocycline. Interestingly, pre-emptive and curative fluorocitrate treatment, which selectively blocks astrocyte and microglia metabolism, 61) inhibits neuropathic pain, 58, 62) whereas the antibiotic minocycline, a specific microglial inhibitor, 63) blocks the development of neuropathic pain states but does not reduce pain that is already established. 59) Although the animal studies men- (Fig. 3 ).
67)
Daily intrathecal administration of the p38 signaling cascade inhibitor SB203580 prevents spinal nerve ligation induced mechanical allodynia, but it cannot reverse neuropathic pain symptoms when given after nerve injury. 68) These observations suggest that the p38 signaling cascade and microglia are only important for the induction or development of neuropathic pain, and a p38 or microglia inhibitor can only treat neuropathic pain at early stages. If true, this limits the therapeutic potential of p38 and microglia inhibitors. Moreover, p38 inhibitors FR167653 or CNI-1493 also prevent the development neuropathic pain symptoms in the spared nerve injury model and in a sciatic inflammatory neuropathy model (Fig. 3) . 69, 70) The CD40-CD154 and P2Y12 inhibitor, suramin, decreases the release of inflammatory cytokines such as IFN-γ, IL-6, and IL-8.
It also prevents the CD154-induced proliferation of human 
71)
Current p38 signaling cascade inhibitors are not isoformspecific due to their design to target common-ATP binding sites on the kinases and the structural similarities between the p38 isoforms. To determine the distinct role of p38 isoforms in the development of neuropathic pain, it is important to specifically inhibit a particular isoform. More importantly, isoform-specific inhibition will minimize the side effects produced by blocking all p38 isoforms with a general inhibitor. A major concern is that p38 signaling cascade inhibitors may produce psychiatric and cardiovascular side effects or liver toxicity. (Fig. 3) . 30) The quinidine homodimer Q2 reverses the P-glycoprotein, an ATP-dependent drug efflux pump, mediated paclitaxel resistance phenotype as well as inhibits verapamilstimulated ATPase activity.
75)
The chemokine CCL2 is released in an activity dependent manner from the central terminals of primary sensory neurons in neuropathic pain conditions. Thacker et al. 38) reported that intraspinal CCL2 activates spinal microglia, 
Targeting the anti-inflammatory cytokines
Research targeting anti-inflammatory glial activation processes, such as cytokine production and/or regulation, for therapeutic purposes is an alternative line to yield some interesting results. Cannabinoid receptors, both type 1 (CB1) and type 2 (CB2), are potential therapeutic targets for inflammatory neurodegenerative diseases and neuropathic pain. 64, 80) Activation of CB2 receptors has beneficial effects in animal models of neuropathic pain. 81) However, one study identified CB2 expression mainly on neurons after chronic neuropathic conditions. 82) The discrepancies between studies may reflect differences in the specificities of the antibodies used for immunohistochemical detection. 88) fall into three major categories: 1) drugs that attenuate microglia and/or astrocyte activation; 2) drugs that inhibit pro-inflammatory cytokine production; and 3) anti-inflammatory drugs.
